184 related articles for article (PubMed ID: 15016317)
1. Molecular footprints of human lung cancer progression.
Yokota J; Kohno T
Cancer Sci; 2004 Mar; 95(3):197-204. PubMed ID: 15016317
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations responsible for metastatic phenotypes of lung cancer cells.
Yokota J; Nishioka M; Tani M; Kohno T
Clin Exp Metastasis; 2003; 20(3):189-93. PubMed ID: 12741677
[TBL] [Abstract][Full Text] [Related]
3. Alterations in p16 and p53 genes and chromosomal findings in patients with lung cancer: fluorescence in situ hybridization and cytogenetic studies.
Demirhan O; Taştemir D; Hastürk S; Kuleci S; Hanta I
Cancer Epidemiol; 2010 Aug; 34(4):472-7. PubMed ID: 20444664
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.
Osada H; Takahashi T
Oncogene; 2002 Oct; 21(48):7421-34. PubMed ID: 12379883
[TBL] [Abstract][Full Text] [Related]
5. How many tumor suppressor genes are involved in human lung carcinogenesis?
Kohno T; Yokota J
Carcinogenesis; 1999 Aug; 20(8):1403-10. PubMed ID: 10426784
[TBL] [Abstract][Full Text] [Related]
6. Prognostic molecular markers in non-small cell lung cancer.
Nikliński J; Niklińska W; Laudanski J; Chyczewska E; Chyczewski L
Lung Cancer; 2001 Dec; 34 Suppl 2():S53-8. PubMed ID: 11720742
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway.
Blanco D; Vicent S; Fraga MF; Fernandez-Garcia I; Freire J; Lujambio A; Esteller M; Ortiz-de-Solorzano C; Pio R; Lecanda F; Montuenga LM
Neoplasia; 2007 Oct; 9(10):840-52. PubMed ID: 17971904
[TBL] [Abstract][Full Text] [Related]
8. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.
Stankovic T; Milinkovic V; Bankovic J; Dinic J; Tanic N; Dramicanin T; Tanic N
Biomed Pharmacother; 2014 Jun; 68(5):521-6. PubMed ID: 24767865
[TBL] [Abstract][Full Text] [Related]
9. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations in mouse lung tumors: implications for cancer chemoprevention.
Herzog CR; Lubet RA; You M
J Cell Biochem Suppl; 1997; 28-29():49-63. PubMed ID: 9589349
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of transplacentally induced mouse lung tumors.
Miller MS; Leone-Kabler S; Rollins LA; Wessner LL; Fan M; Schaeffer DO; McEntee MF; O'Sullivan MG
Exp Lung Res; 1998; 24(4):557-77. PubMed ID: 9659583
[TBL] [Abstract][Full Text] [Related]
12. New molecular approaches to lung cancer: biological and clinical implications of P53, P16 and K-RAS studies.
Niklinska W; Chyczewski L; Niklinski J
Folia Histochem Cytobiol; 2001; 39(2):99-103. PubMed ID: 11374847
[TBL] [Abstract][Full Text] [Related]
13. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers.
Kersting M; Friedl C; Kraus A; Behn M; Pankow W; Schuermann M
J Clin Oncol; 2000 Sep; 18(18):3221-9. PubMed ID: 10986054
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor genes in human lung cancer.
Shimizu E; Sone S
J Med Invest; 1997 Aug; 44(1-2):15-24. PubMed ID: 9395713
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
[TBL] [Abstract][Full Text] [Related]
16. p53 and lung cancer.
Brambilla E; Brambilla C
Pathol Biol (Paris); 1997 Dec; 45(10):852-63. PubMed ID: 9769949
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages.
Wu MS; Shun CT; Sheu JC; Wang HP; Wang JT; Lee WJ; Chen CJ; Wang TH; Lin JT
J Gastroenterol Hepatol; 1998 Mar; 13(3):305-10. PubMed ID: 9570245
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma regulatory pathway in lung cancer.
Wikenheiser-Brokamp KA
Curr Mol Med; 2006 Nov; 6(7):783-93. PubMed ID: 17100603
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
